Of note, this combination treatment effectively shifts the “cold” TME with KRAS mutation into a “hot” environment, leading to the induction of potent anti-tumor activity without any observable adverse effects in both a colorectal cancer model and an aggressive non-small cell lung cancer (NSCLC) model. This evidence concerns the gene KRAS and non-small cell lung carcinoma.